首页> 外文期刊>Diabetes >Combined Risk Allele Score of Eight Type 2 Diabetes Genes Is Associated With Reduced First-Phase Glucose-Stimulated Insulin Secretion During Hyperglycemic Clamps
【24h】

Combined Risk Allele Score of Eight Type 2 Diabetes Genes Is Associated With Reduced First-Phase Glucose-Stimulated Insulin Secretion During Hyperglycemic Clamps

机译:八种2型糖尿病基因的综合风险等位基因评分与高血糖钳制过程中减少的第一阶段葡萄糖刺激的胰岛素分泌相关

获取原文
获取原文并翻译 | 示例
       

摘要

Objective-At least 20 type 2 diabetes loci have now been identified, and several of these are associated with altered β-cell function. In this study, we have investigated the combined effects of eight known β-cell loci on insulin secretion stimulated by three different secretagogues during hyperglycemic clamps.rnResearch Design And Methods-A total of 447 sub jects originating from four independent studies in the Netherlands and Germany (256 with normal glucose tolerance [NGT]/ 191 with impaired glucose tolerance [IGT]) underwent a hyperglycemic clamp. A subset had an extended clamp with additional glucagon-like peptide (GLP)-1 and arginine (n = 224). We next genotyped single nucleotide polymorphisms in TCF7L2, KCNJ11, CDKAL1, IGF2BP2, HHEX/IDE, CDKN2A/B, SLC30A8, and MTNR1B and calculated a risk allele score by risk allele counting.rnResults-The risk allele score was associated with lower first-phase glucose-stimulated insulin secretion (GSIS) (P = 7.1 × 10~(-6)). The effect size was equal in subjects with NGT and IGT. We also noted an inverse correlation with the disposition index (P = 1.6 × 10~(-3)). When we stratified the study population according to the number of risk alleles into three groups, those with a medium- or high-risk allele score had 9 and 23% lower first-phase GSIS. Second-phase GSIS, insulin sensitivity index and GLP-1, or arginine-stimulated insulin release were not significantly different.rnConclusions-A combined risk allele score for eight known β-cell genes is associated with the rapid first-phase GSIS and the disposition index. The slower second-phase GSIS, GLP-1, and arginine-stimulated insulin secretion are not associated, suggest-ing that especially processes involved in rapid granule recruitment and exocytosis are affected in the majority of risk loci.
机译:客观-现已鉴定出至少20个2型糖尿病基因座,其中一些与β细胞功能改变有关。在这项研究中,我们研究了八个已知的β细胞基因座对高血糖钳制过程中三种不同促分泌剂刺激的胰岛素分泌的联合作用。研究设计和方法-共有447个对象来自荷兰和德国的四项独立研究(256葡萄糖耐量正常[NGT] / 191葡萄糖耐量受损[IGT])进行了高血糖钳夹。一个亚组具有额外的胰高血糖素样肽(GLP)-1和精氨酸(n = 224)的扩展钳位。接下来,我们对TCF7L2,KCNJ11,CDKAL1,IGF2BP2,HHEX / IDE,CDKN2A / B,SLC30A8和MTNR1B进行基因分型,并通过风险等位基因计数计算了风险等位基因评分。葡萄糖刺激的胰岛素分泌(GSIS)期(P = 7.1×10〜(-6))。 NGT和IGT受试者的效应大小相同。我们还注意到与处置指数成反比(P = 1.6×10〜(-3))。当我们根据风险等位基因的数量将研究人群分为三类时,那些具有中等或高风险等位基因得分的人其第一阶段GSIS降低了9%和23%。第二阶段的GSIS,胰岛素敏感性指数和GLP-1或精氨酸刺激的胰岛素释放无显着差异。rn结论-八个已知β细胞基因的风险等位基因综合得分与第一阶段的快速GSIS和性状相关指数。第二阶段的GSIS,GLP-1和精氨酸刺激的胰岛素分泌较慢并不相关,这表明在大多数风险基因座中,尤其涉及快速颗粒募集和胞吐的过程受到影响。

著录项

  • 来源
    《Diabetes》 |2010年第1期|287-292|共6页
  • 作者单位

    Department of Molecular Cell Biology, Leiden University Medical Center, Leiden, the Netherlands;

    Diabetes Center, VU University Medical Center, Amsterdam, the Netherlands;

    EMGO Institute for Health and Care Research, VU University Medical Center, Amsterdam, the Netherlands;

    Department of Internal Medicine, Utrecht University Medical Center, Utrecht, the Netherlands;

    Department of Internal Medicine, Eberhard-Karls University of Tuebingen, Tuebingen, Germany;

    Department of Medical Statistics, Leiden University Medical Center, Leiden, the Netherlands;

    Dcpartment of Biological Psychology, VU University, Amsterdam, the Netherlands;

    Department of Molecular Cell Biology, Leiden University Medical Center, Leiden, the Netherlands;

    Department of Molecular Cell Biology, Leiden University Medical Center, Leiden, the Netherlands;

    Department of Molecular Cell Biology, Leiden University Medical Center, Leiden, the Netherlands;

    Diabetes Center, VU University Medical Center, Amsterdam, the Netherlands;

    Diabetes Center, VU University Medical Center, Amsterdam, the Netherlands;

    Diabetes Center, VU University Medical Center, Amsterdam, the Netherlands EMGO Institute for Health and Care Research, VU University Medical Center, Amsterdam, the Netherlands Eli Lilly & Company, Indianapolis, Indiana;

    Department of Molecular Cell Biology, Leiden University Medical Center, Leiden, the Netherlands Diabetes Center, VU University Medical Center, Amsterdam, the Netherlands;

    Department of Internal Medicine, Eberhard-Karls University of Tubingen, Tubingen, Germany;

    Department of Internal Medicine, Eberhard-Karls University of Tubingen, Tubingen, Germany;

    Department of Internal Medicine, Eberhard-Karls University of Tubingen, Tubingen, Germany;

    Department of Medical Statistics, Leiden University Medical Center, Leiden, the Netherlands;

    Dcpartment of Biological Psychology, VU University, Amsterdam, the Netherlands;

    Diabetes Center, VU University Medical Center, Amsterdam, the Netherlands;

    Dcpartment of Biological Psychology, VU University, Amsterdam, the Netherlands;

    EMGO Institute for Health and Care Research, VU University Medical Center, Amsterdam, the Netherlands;

    Department of Internal Medicine, Eberhard-Karls University of Tubingen, Tubingen, Germany;

  • 收录信息 美国《科学引文索引》(SCI);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-18 03:46:36

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号